AstraZeneca has sold US and Canadian rights to its older breast cancer drug Zoladex to TerSera Therapeutics in a deal worth up to $320 million. The deal is good business for AstraZeneca ...

This leaflet was prepared in May 2024. Zoladex, Zoladex SafeSystem and SafeSystem are trade marks of the AstraZeneca group of companies.

This leaflet was prepared in May 2024. Zoladex, Zoladex SafeSystem and SafeSystem are trade marks of the AstraZeneca group of companies.

AstraZeneca beat third-quarter expectations ... in breast cancer treatment earlier this year. Other cancer drugs, Zoladex and Orpathys are experiencing improving demand. But the oncology segment ...

Diversify Wealth Management LLC grew its holdings in shares of AstraZeneca PLC (NASDAQ:AZN – Free Report) by 3.6% during the ...